When one promotional piece promotes several products, a grouped submission sends it once and lets FDA distribute it to every application. It is the biggest efficiency in ad-promo publishing — and the place where a submission can be accepted and still not do what you meant.
Key takeaways
- A grouped submission is distributed to every member application listed in the Application Set of US-Regional.xml.
- All members must share one application type; exactly one is the lead.
- A reused sequence number for any member rejects the whole group.
- Members placed under References are linked, not distributed — the gateway accepts it and nobody is told.
If your promotional material promotes more than one product, you can submit it separately against each application, or once as a grouped submission and let FDA distribute it to every application in the group. For a portfolio of related products sharing campaign material, grouping is the largest efficiency available — and where the sharpest failure modes live.
What a grouped submission actually is
A grouped promotional submission is a single eCTD submission containing promotional materials for more than one product, together with the current labeling for each. Its contents are distributed to every member application: a record is created under each one, using the sequence number given for that application in the US-Regional file, and each record links to the shared contents.
One constraint governs eligibility: every promoted product must be of the same application type. NDAs group with NDAs, BLAs with BLAs. A piece that spans types is submitted separately, or as separate groups by application type.
Lead and members
Every group has exactly one lead and any number of members, distinguished in US-Regional.xml rather than in folders or on the form. All members appear in the Application Set; the Application-Containing-Files attribute is true for the lead and false for every other member; and the lead is listed first.
Each member also carries its own sequence number, unique to that application and never used before. This is the constraint most likely to bite a large portfolio, and the penalty is disproportionate: if any application-and-sequence combination in the group has been used before, the entire group is rejected.
If one member’s sequence number was used before, the whole group is rejected.
References are not an Application Set
US-Regional.xml also has a References section, and putting member applications there looks as if it should work. It does not: references link applications but carry no sequence numbers and distribute nothing. If you are auditing an existing promotional programme for coverage gaps, check this first, because nothing downstream will have flagged it.
What goes in a grouped 2253
| Component | Heading | Rule for groups |
|---|---|---|
| Form FDA 2253 | 1.1 | Marked as a multi-product submission; the application on the form matches the lead in US-Regional.xml |
| Supplemental Application List | 1.1, with the form | Lists each non-lead member: application type and number, product name, date and file name of the current PI |
| Current product labeling | 1.14.6 | Required for every member — a separate PDF per label, or a cross-reference if already submitted |
| Promotional material | 1.15.2 | One set of materials, each linked to every member |
The Supplemental Application List does not replace the Application Set: FDA processes the submission from the US-Regional file and cannot add applications that are not listed there. For grouped submissions that are not 2253s — advisory requests, for example — the cover letter lists every member, and its subject line names the lead and identifies the group.
The rule people most want to break
Every material in a grouped submission must promote every product in the group. Three applications and fifteen materials, five promoting each product, is a batch, not a group — and it is explicitly an error. Grouping exists for genuinely shared material, not for administrative convenience across a campaign.
Before your first group, use OPDP’s test-submission process: the OPDP team reviews the structure and gives feedback before production. Given that one reused sequence number rejects an entire group, it is cheap insurance. This article is general information, not regulatory advice.
Grouped submissions, checked before they go
DnXT Publisher supports US grouped submissions with the lead, members and sequence numbers validated against FDA’s criteria.
